VIII ANNUAL CONFERENCE OF THE BIOMEDICAL RESEARCH TECHNOLOGY PLATFORMS

posted on March 5, 2017
Raúl Insa, SOM Biotech CEO, will participate in the VIII Annual Conference of the Biomedical Research Technology Platforms: Innovative Medicines, Nanomedicine Health Technology and Biotechnology Market. It will be held in Madrid from 24-25 March 2015. Event supported by the Spanish Ministry of Economy, ASEBIO and Farmaindustria. Progress in public-private cooperation, data reutilization for biomedical research and…
continue reading →

DÍA MUNDIAL DE LAS ENFERMEDADES RARAS

posted on February 28, 2017
El próximo martes 28 de febrero, con motivo del Día Mundial de las Enfermedades Raras, SOM Biotech asistirá al evento organizado por FECAMM, FEDER Catalunya y la Plataforma de Malalties Minoritàries, dedicado este año a la investigación y que tendrá lugar en el Hospital Sant Joan de Déu de Barcelona. Más información en Malalties Minoritàries
continue reading →

SOM PRESENTS ITS BUSINESS MODEL AT THE 6TH HEALTHCARE INVESTMENT FORUM

posted on February 12, 2017
The COMB, ESADE BAN, Barcelona Activa and Biocat are together organising the 6th Healthcare Investment Forum, Barcelona 2012. The Forum is the ideal meeting point for companies with biotechnology projects, medical teams, health services and information technologies related to the health industry, and investors interested in this sector.
continue reading →

SOM BIOTECH AT RE(ACT) CONGRESS 2016

posted on February 10, 2017
SOM Biotech will attend next RE(ACT) CONGRESS 2016 (International Congress on Research of Rare and Orphan Diseases) to be held in Barcelona from 9th to 12th of March. The congress aims to bring together world leaders and young scientist from a variety of breaking through scientific field to present cutting edge research, to discuss results and to exchange…
continue reading →

ACUERDO DE COLABORACIÓN ENTRE DUCHENNE PARENT PROJECT ESPAÑA Y SOM BIOTECH.

posted on February 10, 2017
La Asociación Duchenne Parent Project España (DPPE, www.duchenne-spain.org)  y la compañía Biofarmacéutica SOM Biotech han llegado a un acuerdo de colaboración para llevar a cabo el proyecto “Reposicionamiento de Fármacos para la Distrofia Muscular de Duchenne (DMD)”. El equipo de SOM Biotech será el encargado de la identificación in silico de compuestos activos frente a…
continue reading →

JPMORGAN HEALTCARE CONFERENCE 2017

posted on January 30, 2017
SOM Biotech will attend next JP Morgan Healthcare Conference 2017. This event will take place in San Francisco, CA from January 9-12, 2017.  If you are interested in meeting SOM Biotech delegates and knowing more about SOM's current programs, send an email to    [email protected] to arrange a meeting. In addition, SOM Biotech delegates will also be attending the 9th…
continue reading →